Correspondence 0001193125-26-245157 from Connect Biopharma Holdings Ltd (CNTB)
Connect Biopharma Holdings Ltd
Date: May 28, 2026 · CIK: 0001835268 · Accession: 0001193125-26-245157
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295921
Letter
Re: Connect Biopharma Holdings Limited Registration Statement on Form F-3 File No. 333-295921 To the addressees set forth above: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Connect Biopharma Holdings Limited, respectfully requests that the effective date of the Registration Statement on Form F-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on June 1, 2026, or as soon as practicable thereafter. The Registration Statement received a “no review” letter from the Commission. If you have any questions or require additional information, please contact Michael Sullivan, Esq. of Latham & Watkins LLP at (858) 523-3959. Thank you for your assistance and cooperation in this matter.
Connect Biopharma Holdings Limited 3580 Carmel Mountain Road, Suite 200 San Diego, California 92130 May 28, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549
Very truly yours,
CONNECT BIOPHARMA HOLDINGS LIMITED
Show Raw Text
CORRESP 1 filename1.htm CORRESP Connect Biopharma Holdings Limited 3580 Carmel Mountain Road, Suite 200 San Diego, California 92130 May 28, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Connect Biopharma Holdings Limited Registration Statement on Form F-3 File No. 333-295921 To the addressees set forth above: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Connect Biopharma Holdings Limited, respectfully requests that the effective date of the Registration Statement on Form F-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on June 1, 2026, or as soon as practicable thereafter. The Registration Statement received a “no review” letter from the Commission. If you have any questions or require additional information, please contact Michael Sullivan, Esq. of Latham & Watkins LLP at (858) 523-3959. Thank you for your assistance and cooperation in this matter. Very truly yours, CONNECT BIOPHARMA HOLDINGS LIMITED By: /s/ Jeff Cohn Jeff Cohn General Counsel and Corporate Secretary cc: David Szekeres, Connect Biopharma Holdings Limited Michael Sullivan, Latham & Watkins LLP